Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | PAK3 | O75914 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.32 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984026 | 0.77 | CHEK1 (0.56) | ABL1CHEK1 | |
| SCHEMBL12983585 | 0.75 | HDAC6 (0.47) | HDAC6MAOBABL1APPMAPT | |
| SCHEMBL3517783 | 0.75 | CHEK1 (0.62) | HDAC6MAOBCHEK1 | |
| SCHEMBL12983991 | 0.73 | CHEK1 (0.46) | HDAC6CHEK1MAPT | |
| SCHEMBL27260788 | 0.72 | HDAC6 (0.59) | HDAC6MAOBABL1CHEK1APP | |
| SCHEMBL27260556 | 0.71 | HDAC6 (0.54) | HDAC6MAOBABL1APPMAPT | |
| SCHEMBL12122434 | 0.70 | NOS3 (0.37) | — | |
| Hydrochloric Acid SCHEMBL29243663 | 0.69 | HDAC6 (0.52) | HDAC6MAOBABL1APPMAPT | |
| SCHEMBL30471294 | 0.67 | HDAC6 (0.40) | HDAC6MAOBMAPTMAP3K11GPR84 | |
| SCHEMBL27412648 | 0.67 | HDAC6 (0.54) | HDAC6MAOBABL1APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | HDAC6 638/4885MAOB 1403/4885ABL1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.